Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

Completion of Strategic Acquisition Reflected in Q3 Results

FRANKLIN, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE) today announced financial results for the third quarter ended September 30, 2007. For the quarter ended September 30, 2007, net loss was $8,677,000 or $.70 per share, compared to $1,390,000 or $.49 per share, for the same period in 2006. For the nine months ended September 30, 2007, net loss was $10,278,000, or $1.05 per share, compared to $4,229,000 or $1.60 per share, for the same period in 2006. Net loss for the three and nine months ended September 30, 2007 included purchased research and development of $6,556,000 in connection with the strategic acquisition of Echo Therapeutics, Inc. as described in more detail below.

Cash and short term investments totaled $2,218,000 at September 30, 2007, compared to $559,000 at December 31, 2006.

Recent Highlights

The quarter was highlighted by the merger of Sontra Medical Corporation with Echo Therapeutics, Inc. and the surviving Company's name change to Echo Therapeutics, Inc. The merger created a dual platform-enabled transdermal therapeutics and diagnostics company focused on multiple large markets for improved formulations of specialty pharmaceuticals and new applications of next generation transdermal diagnostics for diabetes management and hospital intensive care markets. Echo Therapeutics is now marked by the following key attributes and capabilities:

-- Two transdermal drug penetration technologies, with emphasis on

development and commercialization advanced reformulations of

well-established, FDA-approved products using Echo's AzoneTS dermal

penetration enhancement technology in concert with a 505(b)(2)

regulatory strategy and development of a next generation wireless,

needle-free, continuous transdermal glucose monitor system for the

diabetes home use an
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Available in select spas in the ... Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream provides immediate ... the weakening threat of inflammaging, aging directly caused ... star ingredient GLYCOSEA, a complex of restructuring plankton ... soothing minerals and trace elements. GLYCOSEA works to ...
(Date:4/30/2015)... Sterlitech is proud to offer Synder ... PY, and PZ Polyacrylonotrile (PAN) membranes , as ... to be ideal for oil removal in wastewater ... process requirements where the presence of oils in ... on industrial wastewater discharge and quality requirements for ...
(Date:4/29/2015)... ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial statements ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , 1,703 ... 1,191 , 1,493 , 3,377 , ...
(Date:4/29/2015)... 2015 AlloSource ®, one of ... skin and soft-tissue allografts for use in surgical ... announced the launch of AlloSkin™ AC, an acellular ... Services (CMS) also moved AlloSkin™ RT, a meshed ... high-cost category for reimbursement. "AlloSource is ...
Breaking Biology Technology:Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Sterlitech Offers New Ultrafiltration Membranes 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4AlloSource Announces New Possibilities In Wound Care 2
... fighting to stay on budget as the first quarter of 2009 came to ... a field once thought immune to the troubles of the rest of the ... ... March 23, 2009 -- As the first quarter of 2009 came to a ...
... Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ... its SCORPION(TM) multispecific therapeutic technology at the 100th ... Research (AACR) in Denver. The data presented demonstrated ... CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, ...
... Do winery tasting rooms really help generate sales for ... Innovation Centre almost half of winery tasting room visitors ... visit. , "This research proves that the tasting room ... in future sales," said Dr. Isabelle Lesschaeve, research director, ...
Cached Biology Technology:The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 3The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 4Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 3Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 4Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective 2
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... 2010) Healthy pre-and post-menopausal Japanese women who ... a novel soy germ-based ingredient under development for ... reproductive hormones that stayed within normal limits throughout ... at the American Medical Women,s Association (AMWA) 2010 ...
... inhabited the southern coast of Scandinavia 4,000 years ago ... new study carried out by researchers at Uppsala University ... in the journal BMC Evolutionary Biology , supports ... descended from the Stone Age people in question but ...
... of the zebra finch genome, a new resource has ... thematic series published by BioMed Central, the open access ... As part of the series, a study published in ... related to steroid receptors and estrogen biosynthesis. Researchers writing ...
Cached Biology News:Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 2Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 3Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 4Stone Age Scandinavians unable to digest milk 2
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
... Molecular Probes intensely fluorescent and ... potential for use in a variety ... deliver a strong signal. Unfortunately, protein- ... regions that may cause them to ...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Biology Products: